Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial
Lore Vanderbeke, Nico Janssen, Dennis C. J. J. Bergmans, Marc Bourgeois, Jochem B. Buil, Yves Debaveye, Pieter Depuydt, Simon Feys, Greet Hermans, Oscar Hoiting, Ben van der Hoven, Cato Jacobs, Katrien Lagrou, Virginie Lemiale, Piet Lormans, Johan Maertens, Philippe Meersseman, Bruno Mégarbane, Saad Nseir, Jos A. H. van Oers, Marijke Reynders, Bart Rijnders, Jeroen Schouten, Isabel Spriet, Karin Thevissen, Arnaud W. Thille, Ruth Van Daele, Frank L. van de Veerdonk, Paul E. Verweij, Alexander Wilmer, Roger J. M. Brüggemann, Joost Wauters, the Dutch-Belgian Mycosis Study Group, Bart Rijnders, Paul E. Verweij, Frank L. van de Veerdonk, Alexander Schauwvlieghe, Tom F.W. Wolfs, Joost Wauters, Katrien Lagrou
Topics & Concepts
MedicineIntensive care unitIncidence (geometry)Internal medicinePopulationClinical endpointRandomized controlled trialIntensive care medicineEnvironmental healthPhysicsOpticsAntifungal resistance and susceptibilityFungal Infections and StudiesPneumocystis jirovecii pneumonia detection and treatment